ACST Stock – (NASDAQ: ACST) is actually giving an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the use of its “at the market” equity providing plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering system under which Acasti may well issue as well as market from time to time the common shares of its having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares had been marketed at prevailing market rates averaging US$1.0747 per share. No securities were offered in the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with their services. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and can provide the Company with extra freedom in its continuous review process to explore as well as evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescribed drugs using OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy for lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being developed for people with severe HTG.
Forward Looking Statements – ACST Stock
Statements in this press release which are not statements of current or historical fact constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking assertions involve known and unknown risks, uncertainties, as well as other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any later outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, people are urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the day of this particular press release. Forward-looking assertions in that press release include, but aren’t limited to, statements or information concerning Acasti’s strategy, succeeding operations as well as its review of strategic options.
The forward looking assertions contained in this press release are expressly qualified in their entirety by this alerting declaration, the “Special Note Regarding Forward Looking Statements” area in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor area of Acasti’s website at www.acastipharma.com. Many forward-looking claims in this press release are available as of the particular date of this press release.
ACST Stock – Acasti does not undertake to upgrade some such forward looking statements whether as a consequence of information that is brand new , future events or even otherwise, except as needed by law. The forward-looking assertions contained herein are also subject typically to risks and assumptions as well as uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the use